DrugPatentWatch Database Preview
Capmatinib hydrochloride - Generic Drug Details
What are the generic sources for capmatinib hydrochloride and what is the scope of freedom to operate?
Capmatinib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis Pharm and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Capmatinib hydrochloride has one hundred and forty-nine patent family members in forty-one countries.
One supplier is listed for this compound.
Summary for capmatinib hydrochloride
| International Patents: | 149 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 14 |
| DailyMed Link: | capmatinib hydrochloride at DailyMed |
Recent Clinical Trials for capmatinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Novartis Pharmaceuticals | Phase 3 |
| Institut Bergonié | Phase 3 |
| Institut National de la Santé Et de la Recherche Médicale, France | Phase 3 |
Pharmacology for capmatinib hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | Y | Y | ⤷ Free Forever Trial | ||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ⤷ Free Forever Trial | ||||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | ⤷ Free Forever Trial | ⤷ Free Forever Trial | Y | Y | ⤷ Free Forever Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for capmatinib hydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Chile | 2009001250 | ⤷ Free Forever Trial |
| Spain | 2398843 | ⤷ Free Forever Trial |
| Lithuania | 3034075 | ⤷ Free Forever Trial |
| Brazil | PI0912882 | ⤷ Free Forever Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
